PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity

Core Viewpoint - PainReform Ltd. has announced a strategic acquisition of DeepSolar, an AI-driven solar analytics platform, which is expected to enhance its growth potential while maintaining its commitment to pharmaceutical innovation [1][5][12]. Company Overview - PainReform is a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics, particularly in pain management [14]. - DeepSolar is an AI-powered analytics company that optimizes the efficiency and profitability of solar energy assets through proprietary software and automation tools [2][3]. Acquisition Details - The acquisition agreement includes the transfer of all rights, intellectual property, customer relations, and the "My DeepSolar" application to PainReform [6][11]. - In exchange, BladeRanger Ltd. will receive 178,769 ordinary shares of PainReform, representing 9.9% of its issued share capital, along with various warrants [7][8]. Market Opportunity - The global residential solar market was valued at $94.2 billion in 2024 and is projected to grow at an annual rate of 8% until 2034 [15]. - DeepSolar's technology can reduce operational costs by up to 30%, significantly improving profitability for solar asset owners [3][15]. Strategic Rationale - The acquisition is seen as a unique opportunity for PainReform to enter a high-margin, rapidly growing sector, leveraging DeepSolar's advanced AI capabilities to enhance solar energy efficiency [5][12]. - PainReform aims to capitalize on the technological advantages of DeepSolar to position itself for long-term growth while continuing its focus on pharmaceutical innovation [12][13].